Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT).
Blaise
D
D
Institut Paoli Calmettes, Marseille, France.
Guyotat
D
D
Reiffers
J
J
Olive
D
D
Michallet
M
M
Bellanger
C
C
Vernant
J P
JP
Ifrah
N
N
Attal
M
M
Vilmer
E
E
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003524:Cyclosporins / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007938:Leukemia / Q000601:surgery; D008727:Methotrexate / Q000627:therapeutic use; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D015375:Receptors, Interleukin-2; D008727:Methotrexate